Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P000009/S132

Acticor Sky DR-T 481987; Rivacor Sky DR-T 481982; Rivacor Rise DR-T 482018; Rivacor Aura DR-T 482014

Biotronik, Inc. · Decision date Oct 9, 2026

MEDTECHLEDGER EXPLANATIONP000009/S132

What did the FDA approve?

The FDA record lists this as a real-time process supplement under PMA P000009/S132, with the stated change being a battery separator pocket material change and a new additive to the battery electrolyte. The device category given is implantable dual-chamber defibrillator (product code MRM, Cardiovascular), and the applicant is Biotronik, Inc. The supplement is tied to P000009 by the identifier; the record does not describe the original PMA's full scope, so that scope is not established here.

The decision is recorded as APPR with a date of 2026-10-09. The record does not state the quantities, formulations, test methods, or evidence relied on, so the safety or performance basis for the decision cannot be assessed from these fields. It also does not show which of the four named product lines received which change. A supplement is not an approval of the whole system, and the described purpose is the source's statement rather than independent proof of safety or clinical effectiveness.

FDA approval order statement

battery separator pocket material change and new additive to battery electrolyte.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Oct 9, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P000009/S132
Regulatory pathway
PMA supplement
Product code
MRM
Decision code
APPR
Decision date
Oct 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: DEFIBRILLATOR, IMPLANTABLE, DUAL-CHAMBER.

Product code
MRM
FDA device class
3

For the original device and its historical approval scope, see PMA P000009. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P000009 · Original PMA

    PHYLAX AV ICD SYSTEM

  2. P000009/S132 received

    Application receipt date recorded by FDA.

  3. P000009/S130 · Related supplement

    PSW 2601.U, NEO 2601.U, Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aura DR-T

  4. P000009/S124 · Related supplement

    Ilivia Neo 7 DR-T 429529; Intica Neo 7 DR-T 429558; Intica Neo 5 DR-T 429568

  5. P000009/S133 · Related supplement

    Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aura DR-T, Acticor 7 DR-T, Rivacor 7 DR-T, Rivacor 5 DR-T

  6. P000009/S132 · FDA decision

    Real-Time Process

  7. P000009/S134 · Related supplement

    Intica Neo 7 DR-T DF-1 ProMRI, Intica Neo 5 DR-T DF-1 ProMRI

  8. P000009/S135 · Related supplement

    Ilivia Neo 7 DRT, Intica Neo 7 DRT, Intica Neo 5 DRT, Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aur

Timeline entries are records held by MedtechLedger for P000009. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P000009

Explore the linked device profile

Other records with product code MRM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records